← All Spyglass Pharma, INC filings

Spyglass Pharma, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
SGP
Spyglass Pharma, INC
10-Q: SpyGlass Pharma Reports Q1 2026 Results, Focus on Glaucoma Treatment
SpyGlass Pharma, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Phase 3 clinical trials for the BIM-IOL System aimed at treating glaucoma.